Skip to main content

Table 1 Demographic and Clinical Measures of Study Participants

From: Transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of pediatric nephrotic syndrome: a pilot study

ID Diagnosis Age Sex Duration of disease
(years)
Previous Medications Change in UPC Serum albumin (mg/dl) # Relapses in previous 12 months # Relapses during taVNS study
        Baseline 6 months   
001 FRNS 4 M 1.5 - - - 3 0
002 8 M 5 MMF - - 4 0
003 8 M 4 MMF - - 4 0
004 SRNS:
FSGS
7 M 2.7 tacrolimus, enalapril, prednisolone -76% 3.3 3.3 - -
005 11 F 3.8 tacrolimus, enalapril, prednisolone -36% 4.7 4.8 - -
006 17 F 3.3 tacrolimus, enalapril, prednisolone -25% 4.5 4.6 - -
007 SRNS:
Congenital
Nephrotic
12 F 12 tacrolimus, enalapril, losartan prednisolone -13.7% 2.5 2.4 - -
  1. FRNS- frequently relapsing nephrotic syndrome; SRNS- steroid resistant nephrotic syndrome; FSGS- focal segmental glomerulosclerosis; M- male; F- female; MMF- mycophenolate mofetil; UPC- urine protein:creatinine; taVNS- transcutaneous auricular vagus nerve stimulation